UTAA91 injection for systemic sclerosis study
Treatments studied
Part of Skin clinical trials.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your systemic sclerosis is active and moderate to severe, and standard treatments haven't worked or aren't an option.
- Your liver, kidney, heart, and lungs are working well enough for the study.
- You do not have a serious mental health condition that would interfere with the trial.
- You are not pregnant or breastfeeding, and if applicable, you agree to avoid pregnancy for 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This early-stage trial tests whether HN2302, a new type of genetic medicine, is safe and helps patients with lupus or systemic sclerosis. Researchers want to see if it can reduce symptoms and improve organ function in people with these autoimmune conditions.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.